InNeuroCo has been acquired by Integer
The owners of InNeuroCo has sold the company to Integer (NYSE:ITGR).
Founded in 2014 and headquartered in Pembroke Pines, Florida, InNeuroCo is a leading founder-owned designer and contract manufacturer of ultra-precise, highly engineered neurovascular catheters. InNeuroCo’s primary products are single-use catheters principally used in interventional neurovascular procedures for the treatment of ischemic strokes and aneurysms. Offering turnkey product design and development, supported by comprehensive domestic manufacturing capabilities, InNeuroCo serves as a mission-critical supply partner to the world’s preeminent medical device OEMs.
With approximately US$1.4 billion in annual revenue, Integer is one of the largest medical devices outsource manufacturers in the world, serving the cardiac, vascular, rhythm management and neuromodulation markets.
Oaklins TM Capital in the US served as the exclusive financial advisor to InNeuroCo in its sale to Integer (NYSE:ITGR).
Marc Litzenberg
President and CEO, InNeuroCo
Sprechen Sie mit dem Deal Team
James McLaren
Oaklins TM Capital
Michael S. Goldman
Oaklins TM Capital
John Dean
Oaklins TM Capital
Bradley S. Goldstein
Oaklins TM Capital
Ariel Fieldman
Oaklins TM Capital
Transaktionen
CARSO Group has acquired a majority stake in AQCF Group
CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.
Mehr erfahrenPrestige Inhome Care has found a long-term strategic partner
Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
Mehr erfahrenCara Care has been acquired by Mahana Therapeutics
Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.
Mehr erfahren